Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996527 · ClinicalTrials.gov registry record · Early Phase 1
3T MRI Biomarkers of Glioma Treatment Response
A Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT01996527 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 7 participants.
The verdict
NCT01996527, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma. New diagnostic procedures, such as advanced MRI techniques at 3 Tesla, may be more effective than standard MRI in measuring treatment response in patients receiving treatment for high-grade gliomas.
Interventions
- DEVICE DCE-MRI
- DEVICE 3-Tesla magnetic resonance imaging
- DEVICE CEST-MRI
- DEVICE DW-MRI
- DEVICE DSC-MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01996527
The ClinicalTrials.gov registry entry for NCT01996527 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which DCE-MRI is the first listed.
NCT01996527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01996527 about?
NCT01996527 is a clinical study titled "3T MRI Biomarkers of Glioma Treatment Response". This pilot clinical trial studies advanced magnetic resonance imaging (MRI) techniques in measuring treatment response in patients with high-grade glioma. New diagnostic procedures, such as advanced MRI techniques at 3 Tesla, may be more effective than standard MRI in measuring treatment response in...
What is the current status of trial NCT01996527?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2012-05. Estimated completion is 2016-01-01.
What interventions are being tested in trial NCT01996527?
The interventions under investigation include: DCE-MRI (DEVICE), 3-Tesla magnetic resonance imaging (DEVICE), CEST-MRI (DEVICE), DW-MRI (DEVICE), DSC-MRI (DEVICE).
Who is sponsoring clinical trial NCT01996527?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.